Sugi Predict

Sugi Predict / Compounds / SCHEMBL20699355

SCHEMBL20699355

SCHEMBL20699355

Fc1cc(Br)cc2c1cnn2C1CCCCO1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP4F2 P78329 3/20 0.45
▸ CYP4A11 Q02928 3/20 0.45
▸ RXRA P19793 1/20 0.42
▸ RXRB P28702 1/20 0.42
▸ RXRG P48443 1/20 0.42
▸ KDM5A P29375 1/20 0.40
▸ ALDH1A1 P00352 3/20 0.40
▸ LMNA P02545 2/20 0.40
▸ POLB P06746 2/20 0.40
▸ IDO1 P14902 1/20 0.34
▸ TDO2 P48775 1/20 0.34
▸ ESR1 P03372 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ ATR Q13535 6/20 0.33
▸ RET P07949 1/20 0.32
▸ PDE1A P54750 1/20 0.32
▸ PDE1B Q01064 1/20 0.32
▸ PDE1C Q14123 1/20 0.32
▸ PDE9A O76083 1/20 0.32
▸ KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29921466 1.00 CYP4F2 (0.45) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL21196054 0.86 CYP4F2 (0.46) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL30950246 0.84 CYP4F2 (0.45) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL30811797 0.84 RXRA (0.42) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL29176223 0.84 RXRA (0.42) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL21196196 0.84 CYP4F2 (0.45) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL20699339 0.84 RXRA (0.42) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL1709840 0.84 CYP4F2 (0.45) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL29003306 0.84 RXRA (0.44) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL30161576 0.84 RXRA (0.42) CYP4F2CYP4A11RXRARXRBRXRG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260085062-A1 NOVEL COMPOUNDS AS CK2 INHIBITORS CAMBRIDGE ENTPR LTD (GB) 2026-03-26 — — US disclosed
WO-2025217560-A1 TRIAZOLO INDAZOLE COMPOUNDS AS JAK INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2025-10-16 — — WO disclosed
EP-4584249-A1 NOVEL COMPOUNDS AS CK2 INHIBITORS Cambridge Enterprise Limited (GB) 2025-07-16 — — EP disclosed
CN-116964046-B PLK4 inhibitors and uses thereof 上海齐鲁制药研究中心有限公司 2024-04-19 — — CN disclosed
WO-2024052702-A1 NOVEL COMPOUNDS AS CK2 INHIBITORS CAMBRIDGE ENTERPRISE LIMITED (GB) 2024-03-14 — — WO disclosed
CN-117529476-A Preparation of substituted 1, 2-diamino heterocyclic derivatives and their use as medicaments 亚飞络思制药公司 2024-02-06 — — CN disclosed
CN-116964046-A PLK4 inhibitors and uses thereof 上海齐鲁制药研究中心有限公司 2023-10-27 — — CN disclosed
CN-113004252-B Aryl imidazole derivative and application thereof 江苏先声药业有限公司 2023-06-09 — — CN disclosed
CN-111032646-B Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors 施万生物制药研发IP有限责任公司 2023-01-03 — — CN disclosed
WO-2022184049-A1 PLK4 INHIBITOR AND USE THEREOF 上海齐鲁制药研究中心有限公司 2022-09-09 — — WO disclosed
US-10538513-B2 Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2020-01-21 — — US disclosed
US-10538513-B2 Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2020-01-21 — — US disclosed
US-20190315724-A1 PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2019-10-17 — — US disclosed
US-20190315724-A1 PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2019-10-17 — — US disclosed
US-10392368-B2 Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2019-08-27 — — US disclosed
US-10392368-B2 Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2019-08-27 — — US disclosed
WO-2019027960-A1 PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2019-02-07 — — WO disclosed
WO-2019027960-A1 PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2019-02-07 — — WO disclosed
US-20190040043-A1 PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2019-02-07 — — US disclosed
US-20190040043-A1 PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2019-02-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190315724-A1 PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS JAK3, JAK1, JAK2 CYP4F2 2191/4885CYP4A11 933/4885RXRA 3296/4885
US-20190040043-A1 PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS JAK3, JAK1, JAK2 CYP4F2 2191/4885CYP4A11 933/4885RXRA 3296/4885
US-10392368-B2 Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors JAK3, JAK1, JAK2 CYP4F2 2191/4885CYP4A11 933/4885RXRA 3296/4885
US-20260085062-A1 NOVEL COMPOUNDS AS CK2 INHIBITORS CSNK1A1, CSNK1G1, CSNK2A3 CYP4F2 3172/4885CYP4A11 2221/4885RXRA 2600/4885
US-10538513-B2 Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors JAK3, JAK1, JAK2 CYP4F2 2191/4885CYP4A11 933/4885RXRA 3296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.